New drug cocktail aims to tackle tough stomach cancer
NCT ID NCT01991379
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two drugs, MEK162 and imatinib (Gleevec), in people with advanced gastrointestinal stromal tumor (GIST). The first part finds the safest dose, and the second part checks how well the combo shrinks tumors. About 75 participants will take part, including those who have not had treatment before.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MEK162 (binimetinib) and imatinib mesylate (Gleevec)
What this could lead to
If successful, this combination could offer a new first-line treatment option for advanced GIST, potentially improving response rates and delaying disease progression.
What could go wrong
This is an early-phase trial (Ib/II) with a small number of participants, so the benefits and risks are not yet fully known. The combination may cause side effects or not work better than imatinib alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMOR (GIST) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States